Particularly, the identification of serine 325 as the phosphorylation site mediating NFYa degradation recognized a key regulatory molecular switch, as well as a potential target for modulating NFYa activity in metabolic disorders or developmental abnormalities. Here, NFYA is linked to metabolic disease.